[go: up one dir, main page]

MXPA05011418A - Metodo para administracion de troxacitabina. - Google Patents

Metodo para administracion de troxacitabina.

Info

Publication number
MXPA05011418A
MXPA05011418A MXPA05011418A MXPA05011418A MXPA05011418A MX PA05011418 A MXPA05011418 A MX PA05011418A MX PA05011418 A MXPA05011418 A MX PA05011418A MX PA05011418 A MXPA05011418 A MX PA05011418A MX PA05011418 A MXPA05011418 A MX PA05011418A
Authority
MX
Mexico
Prior art keywords
troxacitabine
administration
tumor
cancer
host
Prior art date
Application number
MXPA05011418A
Other languages
English (en)
Inventor
Henriette Gourdeau
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Publication of MXPA05011418A publication Critical patent/MXPA05011418A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

En el tratamiento del cancer, pueden ser administradas la troxacitabina o una sal aceptable farmaceuticamente de la misma a un hospedero el cual tiene un tumor, por infusion continua por un periodo de por lo menos 72 horas, en donde la cantidad es suficiente para proporcionar reduccion tumoral.
MXPA05011418A 2003-04-25 2004-03-24 Metodo para administracion de troxacitabina. MXPA05011418A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46522803P 2003-04-25 2003-04-25
PCT/CA2004/000446 WO2004096239A1 (en) 2003-04-25 2004-03-24 Method for administration of troxacitabine

Publications (1)

Publication Number Publication Date
MXPA05011418A true MXPA05011418A (es) 2006-01-23

Family

ID=33418206

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011418A MXPA05011418A (es) 2003-04-25 2004-03-24 Metodo para administracion de troxacitabina.

Country Status (3)

Country Link
US (1) US20040248915A1 (es)
MX (1) MXPA05011418A (es)
WO (1) WO2004096239A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441568A1 (en) * 2001-03-23 2002-10-03 Shire Biochem Inc. Pharmaceutical combinations for the treatment of cancer
AU2006324155A1 (en) * 2005-12-09 2007-06-21 Drugtech Corporation Intravenous essential fatty acid emulsion
WO2011112889A2 (en) * 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services β-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY
WO2019133791A1 (en) * 2017-12-28 2019-07-04 Ackler Scott Formulations, systems, and methods for therapeutic treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US6350753B1 (en) * 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
AU2195297A (en) * 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
DK1165096T3 (da) * 1999-03-29 2010-01-25 Shire Canada Inc Anvendelse af cytidinderivater til behandling af leukæmi
CA2441568A1 (en) * 2001-03-23 2002-10-03 Shire Biochem Inc. Pharmaceutical combinations for the treatment of cancer
AU2002242561A1 (en) * 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine

Also Published As

Publication number Publication date
US20040248915A1 (en) 2004-12-09
WO2004096239A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
EG25822A (en) Quinolinyl-pyrrolopyrazoles
AU2003267203A8 (en) Method for administering thermotherapy to prevent the growth of tumors
NZ589445A (en) Rasagiline for parkinson's disease modification
IL189546A0 (en) Therapy for the treatment of disease
AP1529A (en) Therapeutic formulation for administering tolterodine with controlled release.
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
SI1551409T1 (sl) Uporaba kinazolinskega derivata ZD6474, kombiniranega z gemcitabinom in po želji ionizirajočim obsevanjem, pri zdravljenju raka
CA2464758A1 (en) Combination therapy comprising zd6474 and a taxane
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
PL1689404T3 (pl) Połączenie ET-743 z pro lekami 5-fluorouracylu do leczenia raka
EP2292226A3 (en) The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
AU7040201A (en) A new use for deferiprone
MXPA05011418A (es) Metodo para administracion de troxacitabina.
NZ587941A (en) Methods to inhibit tumor cell growth by using lansoprazole
WO2005055933A3 (en) Treatment of psoriasis with rosiglitazone
PL1732551T3 (pl) Perheksylina do leczenia przewlekłej niewydolności serca
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
EP1622450A4 (en) PROCESS FOR PROMOTING UNINTERRUPTED SLEEP BY ADMINISTERING TROPIUM CHLORIDE
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.
AU4258601A (en) Divided dose therapies with vascular damaging activity
IL159770A0 (en) Calcium salts with cytotoxic activity
WO2003072019A3 (en) Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog
RU2004105675A (ru) Способ комплексного лечения язв роговицы
EP1547596A4 (en) MEDICAL COMPOSITION AND METHOD FOR THE TREATMENT OF MALIGNANT TUMORS AND THE USE THEREOF

Legal Events

Date Code Title Description
FA Abandonment or withdrawal